• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: H.I.G. Ventures - Clarus, Llc was granted 5,692,381 shares

    10/4/21 4:09:50 PM ET
    $BLUWU
    Business Services
    Finance
    Get the next $BLUWU alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    H.I.G. Ventures - Clarus, LLC

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Clarus Therapeutics Holdings, Inc. [ CRXT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/09/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/09/2021 A(1) 490,531 A $0.00 490,531 I See Footnote(2)
    Common Stock 09/09/2021 A(1) 2,731,094 A $0.00 2,731,094 I See Footnote(3)
    Common Stock 09/09/2021 A(1) 2,470,756 A $0.00 2,470,756 I See Footnote(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    H.I.G. Ventures - Clarus, LLC

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H.I.G. Bio-Clarus II, L.P.

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H.I.G. Bio-Clarus I, L.P.

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    H.I.G.-GPII, Inc.

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    TAMER ANTHONY

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    MNAYMNEH SAMI

    (Last) (First) (Middle)
    C/O H.I.G. CAPITAL, 1450 BRICKELL AVE.,
    SUITE 3100

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    Explanation of Responses:
    1. Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer.
    2. The shares reported are held of record by H.I.G. Bio -- Clarus I, L.P ("Clarus I"). H.I.G.-GPII, Inc. ("H.I.G. GP") is the general partner of Clarus I and has sole voting and investment control over the shares owned by Clarus I. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus I. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
    3. The shares reported are held of record by H.I.G. Ventures - Clarus, LLC ("H.I.G. Ventures"). H.I.G. GP is the manager of H.I.G. Ventures and has sole voting and investment control over the shares owned by H.I.G. Ventures. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by H.I.G. Ventures. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
    4. The shares reported are held of record by H.I.G. Bio -- Clarus II, L.P ("Clarus II"). H.I.G. GP is the general partner of Clarus II and has sole voting and investment control over the shares owned by Clarus II. Mr. Tamer and Mr. Mnaymneh are the sole shareholders of H.I.G. GP and may be deemed to share beneficial ownership of the shares held by Clarus II. Each of Mr. Tamer and Mr. Mnaymneh disclaims beneficial ownership of the shares reported herein except to the extent of their pecuniary interest, if any.
    H.I.G. Ventures - Clarus LLC By: H.I.G.-GP II, Inc., its manager By: /s/ Richard Siegel _Title: Authorized Signatory 10/04/2021
    H.I.G. Bio - Clarus II, L.P. By: H.I.G.-GP II, Inc., its general partner By: /s/ Richard Siegel _Title: Authorized Signatory 10/04/2021
    H.I.G. Bio - Clarus I, L.P. By: H.I.G.-GP II, Inc., its general partner By: /s/ Richard Siegel Title: Authorized Signatory 10/04/2021
    H.I.G.-GP II, Inc. By: /s/ Richard Siegel Title: Authorized Signatory 10/04/2021
    By: /s/ Anthony Tamer 10/04/2021
    By: /s/ Sami Mnaymneh 10/04/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BLUWU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLUWU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLUWU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: H.I.G. Ventures - Clarus, Llc was granted 5,692,381 shares

    4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

    10/4/21 4:09:50 PM ET
    $BLUWU
    Business Services
    Finance

    SEC Form 3 filed by new insider H.I.G. Ventures - Clarus, Llc

    3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

    10/4/21 4:07:54 PM ET
    $BLUWU
    Business Services
    Finance

    SEC Form 3: New insider Cbc Spvi Ltd claimed ownership of 3,602,287 units of Common Stock

    3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

    9/24/21 6:05:09 AM ET
    $BLUWU
    Business Services
    Finance

    $BLUWU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Blue Water Moves to Secure Court Approval for $10 Billion CITGO Acquisition Plan

    WILMINGTON, Del., Sept. 30, 2025 /PRNewswire/ -- Blue Water Venture Partners, LLC ("Blue Water"), an entity affiliated with Joseph Hernandez, the Chairman and Chief Executive Officer of Blue Water Acquisition Corp III ("BWAC III") announced today that it has formally requested approval from the United States District Court for the District of Delaware to consider its unsolicited $10 billion bid for the assets of CITGO Petroleum Corporation. The motion, filed September 12, 2025, in the matter of Crystallex International Corp. v. Bolivarian Republic of Venezuela (Case No. 17-mc-

    9/30/25 6:00:00 AM ET
    $BLUWU
    Business Services
    Finance

    /C O R R E C T I O N -- Blue Water Acquisition Corp iii/

    In the news release, Blue Water Advances in CITGO Bidding Process, issued 15-Sep-2025 by Blue Water Acquisition Corp iii over PR Newswire, we are advised by the company that the media contact was omitted from the text. The complete, corrected release follows: Blue Water Advances in CITGO Bidding Process NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Blue Water Venture Partners, LLC ("Blue Water"), an entity affiliated with Joeseph Hernandez, the Chairman and Chief Executive Officer of Blue Water Acquisition Corp. III (Nasdaq: "BLUWU"), announced today that it has received court approval to enter into a non-disclosure agreement with the Special Master, granting access to the confidential data ro

    9/15/25 5:27:00 PM ET
    $BLUWU
    Business Services
    Finance

    Blue Water Advances in CITGO Bidding Process

    NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Blue Water Venture Partners, LLC ("Blue Water"), an entity affiliated with Joeseph Hernandez, the Chairman and Chief Executive Officer of Blue Water Acquisition Corp. III (Nasdaq: "BLUWU"), announced today that it has received court approval to enter into a non-disclosure agreement with the Special Master, granting access to the confidential data room established for the CITGO sale. Blue Water continues to assert that its proposal represents the most compelling and beneficial path forward for all stakeholders. Blue Water's $10 billion b

    9/15/25 5:27:00 PM ET
    $BLUWU
    Business Services
    Finance

    $BLUWU
    SEC Filings

    View All

    SEC Form 10-Q filed by Blue Water Acquisition Corp.

    10-Q - Blue Water Acquisition Corp. III (0002050501) (Filer)

    8/14/25 4:07:21 PM ET
    $BLUWU
    Business Services
    Finance

    SEC Form SCHEDULE 13G filed by Blue Water Acquisition Corp.

    SCHEDULE 13G - Blue Water Acquisition Corp. III (0002050501) (Subject)

    8/12/25 11:14:56 AM ET
    $BLUWU
    Business Services
    Finance

    SEC Form SCHEDULE 13G filed by Blue Water Acquisition Corp.

    SCHEDULE 13G - Blue Water Acquisition Corp. III (0002050501) (Subject)

    8/8/25 8:25:41 AM ET
    $BLUWU
    Business Services
    Finance

    $BLUWU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Blue Water Acquisition Corp. (Amendment)

    SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

    10/8/21 4:24:24 PM ET
    $BLUWU
    Business Services
    Finance

    SEC Form SC 13G filed by Blue Water Acquisition Corp.

    SC 13G - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

    9/24/21 6:06:39 AM ET
    $BLUWU
    Business Services
    Finance

    SEC Form SC 13D filed by Blue Water Acquisition Corp.

    SC 13D - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

    9/21/21 4:18:31 PM ET
    $BLUWU
    Business Services
    Finance